Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mitie Group plc stock logo
MITFY
Mitie Group
$8.52
+2.1%
$7.32
$5.25
$8.59
$2.67B0.9511,069 shs1,511 shs
MonotaRO Co., Ltd. stock logo
MONOY
MonotaRO
$20.30
-2.8%
$19.54
$10.29
$21.63
$10.18B0.8480,983 shs35,107 shs
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
$7.67
-3.5%
$6.73
$3.93
$7.99
$10.09B1.314,231 shs671 shs
Sino Biopharmaceutical Limited stock logo
SBMFF
Sino Biopharmaceutical
$0.57
+1.9%
$0.49
$0.31
$0.57
$10.75B0.51,709 shs311 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mitie Group plc stock logo
MITFY
Mitie Group
-2.51%+0.36%+4.25%+39.93%+37.40%
MonotaRO Co., Ltd. stock logo
MONOY
MonotaRO
+1.65%+3.32%+10.18%+20.83%+98.86%
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
0.00%+5.44%+19.22%+22.91%+78.63%
Sino Biopharmaceutical Limited stock logo
SBMFF
Sino Biopharmaceutical
0.00%+13.35%+13.70%+32.33%+53.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Mitie Group plc stock logo
MITFY
Mitie Group
1.097 of 5 stars
0.03.01.70.01.90.01.3
MonotaRO Co., Ltd. stock logo
MONOY
MonotaRO
2.1527 of 5 stars
0.05.01.70.03.00.01.3
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
N/AN/AN/AN/AN/AN/AN/AN/A
Sino Biopharmaceutical Limited stock logo
SBMFF
Sino Biopharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Mitie Group plc stock logo
MITFY
Mitie Group
3.00
BuyN/AN/A
MonotaRO Co., Ltd. stock logo
MONOY
MonotaRO
0.00
N/AN/AN/A
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
4.00
Strong BuyN/AN/A
Sino Biopharmaceutical Limited stock logo
SBMFF
Sino Biopharmaceutical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Mitie Group plc stock logo
MITFY
Mitie Group
$5.59B0.48$1.30 per share6.54$1.79 per share4.76
MonotaRO Co., Ltd. stock logo
MONOY
MonotaRO
$1.91B5.34$0.51 per share39.60$1.37 per share14.82
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
$15.88B0.64$2.89 per share2.65$16.33 per share0.47
Sino Biopharmaceutical Limited stock logo
SBMFF
Sino Biopharmaceutical
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Mitie Group plc stock logo
MITFY
Mitie Group
$158.76MN/A0.0012.90N/AN/AN/AN/A6/5/2025 (Estimated)
MonotaRO Co., Ltd. stock logo
MONOY
MonotaRO
$173.82M$0.4547.2144.13N/A9.09%33.75%24.22%7/30/2025 (Estimated)
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
$2.58B$1.864.12N/A17.21%11.16%1.13%7/30/2025 (Estimated)
Sino Biopharmaceutical Limited stock logo
SBMFF
Sino Biopharmaceutical
N/AN/A0.00N/AN/AN/AN/A6/4/2025 (Estimated)

Latest MITFY, MONOY, RAIFY, and SBMFF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
N/A$0.54N/A$0.54N/A$2.39 billion
5/1/2025Q1 2025
MonotaRO Co., Ltd. stock logo
MONOY
MonotaRO
N/A$0.10N/A$0.10$554.00 million$518.86 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Mitie Group plc stock logo
MITFY
Mitie Group
$0.101.17%N/AN/AN/A
MonotaRO Co., Ltd. stock logo
MONOY
MonotaRO
$0.070.34%N/A15.56%N/A
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
$0.182.35%N/A9.68%N/A
Sino Biopharmaceutical Limited stock logo
SBMFF
Sino Biopharmaceutical
N/AN/AN/AN/AN/A

Latest MITFY, MONOY, RAIFY, and SBMFF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/20/2025
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
$0.29834/1/20254/1/20254/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Mitie Group plc stock logo
MITFY
Mitie Group
0.63
0.90
0.89
MonotaRO Co., Ltd. stock logo
MONOY
MonotaRO
0.01
2.58
2.01
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
N/A
5.09
5.09
Sino Biopharmaceutical Limited stock logo
SBMFF
Sino Biopharmaceutical
0.02
1.15
1.07

Institutional Ownership

CompanyInstitutional Ownership
Mitie Group plc stock logo
MITFY
Mitie Group
0.15%
MonotaRO Co., Ltd. stock logo
MONOY
MonotaRO
0.06%
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
N/A
Sino Biopharmaceutical Limited stock logo
SBMFF
Sino Biopharmaceutical
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Mitie Group plc stock logo
MITFY
Mitie Group
68,145313.92 million312.91 millionNot Optionable
MonotaRO Co., Ltd. stock logo
MONOY
MonotaRO
1,375501.35 millionN/ANot Optionable
Raiffeisen Bank International AG stock logo
RAIFY
Raiffeisen Bank International
44,8871.32 billionN/ANot Optionable
Sino Biopharmaceutical Limited stock logo
SBMFF
Sino Biopharmaceutical
25,80618.79 billionN/ANot Optionable

Recent News About These Companies

SBMFF Sino Biopharmaceutical Limited
3 Promising Penny Stocks With Market Caps Under US$11B

Media Sentiment Over Time

Mitie Group stock logo

Mitie Group OTCMKTS:MITFY

$8.52 +0.18 (+2.10%)
As of 02:43 PM Eastern

Mitie Group plc, together with its subsidiaries, provides facilities management and professional services in the United Kingdom and internationally. The company operates in four segments: Business Services, Technical Services, Central Government & Defense (CG&D), Communities. The company provides decarbonization, electrical grid connections, emission intelligence, energy and carbon, EV fleets, and heat solutions, as well as solar energy; cleaning and hygiene, engineering maintenance, integrated facilities management, landscape, and waste management services; project and workplace services; and Fire & security systems, front of house, intelligence, vetting, and security guarding service. It serves to financial, professional, life science, manufacturing, media, telecom and tech, retail, shopping centres, transport, utilities, central and local government, critical environment, defence, education, healthcare, and justice and immigration sectors. The company was incorporated in 1936 and is headquartered in London, the United Kingdom.

MonotaRO stock logo

MonotaRO OTCMKTS:MONOY

$20.30 -0.58 (-2.78%)
As of 03:50 PM Eastern

MonotaRO Co., Ltd., together with its subsidiaries, operates an online MRO products store in Japan and internationally. The company offers safety protective equipment, work clothes, and safety shoes; logistics, storage, and packing supplies; tapes; safety, disaster prevention, and crime prevention products; safety signs; ship and fishing supplies; office supplies; office furniture/lighting/cleaning supplies; cutting tools and abrasives; measurement and surveying equipment; hand tools/electric and pneumatic tools; sprays, oils, greases, and paints; adhesives and repair materials; welding supplies; and piping and water related components/pumps/pneumatic and hydraulic equipment/hoses. It also provides mechanical parts; control equipment; soldering and anti-static products; architectural hardware, building materials, painting, and interior supplies; air conditioning and electrical equipment; electrical materials; screws, bolts, nails, and materials; automotive supplies; truck supplies; motorcycle supplies; bicycle supplies; scientific research and development supplies; clean room supplies; kitchen equipment and store supplies; agricultural and gardening supplies; and medical and nursing supplies. It serves factories, construction, automobile maintenance, and other industries. The company was formerly known as Sumisho Grainger Co., Ltd. and changed its name to MonotaRO Co., Ltd. in February 2006. The company was incorporated in 2000 and is headquartered in Osaka, Japan. MonotaRO Co., Ltd. operates as a subsidiary of Grainger Global Holdings, Inc.

Raiffeisen Bank International stock logo

Raiffeisen Bank International OTCMKTS:RAIFY

$7.67 -0.28 (-3.46%)
As of 02:24 PM Eastern

Raiffeisen Bank International AG, together with its subsidiaries, offers banking services to corporate, private customers, and institutional customers. The company offers cash management, cross border accounts, electronic banking, payments solutions, sustainable and subsidized financing, leveraged and acquisition financing, project and structured financing, real estate financing, leasing, factoring, trade and export financing, investment banking, investing, hedging, and investor services to its institutional clients and corporate customers in agri food and beverage, automotive, construction and building materials, food and beverage, healthcare and pharmaceuticals, oil and gas, packaging, real estate, retail, technology, telecom, and utilities industries. It also provides retail and private banking services, including deposits, loans, wealth management, and advisory services to retail customers and small and medium-sized enterprises. In addition, the company offers clearing, reporting, settlement, guarantees, letters of credit, fund administration, acceptances, brokerage, asset management, and custody services; and investment banking services, including asset based finance, fund finance and alternatives investments, loan syndication, mergers and acquisitions advisory, and debt and equity capital markets services. It operates through a network of business outlets in Central, Southeastern, and Eastern Europe, as well as Austria, Czech Republic, Hungary, Poland, and Slovakia. Raiffeisen Bank International AG was founded in 1886 and is based in Vienna, Austria.

Sino Biopharmaceutical stock logo

Sino Biopharmaceutical OTCMKTS:SBMFF

$0.57 +0.01 (+1.94%)
As of 11:42 AM Eastern

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.